Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Oncocyte Agrees to Enter Licensing and Collaboration Agreement with Chronix Biomedical

Oncocyte Corporation, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has agreed to enter a licensing and collaboration agreement with Chronix Biomedical. Oncocyte is licensing Chronix’s patented CNI Monitor technology for the TheraSure™-CNI MONITOR clinical assay. Read more >>

Share this post